Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 18.84
MDVN's Cash to Debt is ranked lower than
54% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 49.03 vs. MDVN: 18.84 )
Ranked among companies with meaningful Cash to Debt only.
MDVN' s Cash to Debt Range Over the Past 10 Years
Min: 1.1  Med: N/A Max: No Debt
Current: 18.84
Equity to Asset 0.32
MDVN's Equity to Asset is ranked lower than
82% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. MDVN: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
MDVN' s Equity to Asset Range Over the Past 10 Years
Min: -0.02  Med: 0.5 Max: 0.99
Current: 0.32
-0.02
0.99
F-Score: 5
Z-Score: 6.19
M-Score: -2.80
WACC vs ROIC
11.43%
-41.01%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -25.04
MDVN's Operating margin (%) is ranked higher than
61% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -82.26 vs. MDVN: -25.04 )
Ranked among companies with meaningful Operating margin (%) only.
MDVN' s Operating margin (%) Range Over the Past 10 Years
Min: -510.27  Med: -33.39 Max: 43.96
Current: -25.04
-510.27
43.96
Net-margin (%) -17.24
MDVN's Net-margin (%) is ranked higher than
63% of the 740 Companies
in the Global Biotechnology industry.

( Industry Median: -80.77 vs. MDVN: -17.24 )
Ranked among companies with meaningful Net-margin (%) only.
MDVN' s Net-margin (%) Range Over the Past 10 Years
Min: -496.58  Med: -38.58 Max: 38.91
Current: -17.24
-496.58
38.91
ROE (%) -24.74
MDVN's ROE (%) is ranked higher than
57% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: -32.29 vs. MDVN: -24.74 )
Ranked among companies with meaningful ROE (%) only.
MDVN' s ROE (%) Range Over the Past 10 Years
Min: -862.65  Med: -91.55 Max: 110.4
Current: -24.74
-862.65
110.4
ROA (%) -13.90
MDVN's ROA (%) is ranked higher than
63% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: -26.97 vs. MDVN: -13.90 )
Ranked among companies with meaningful ROA (%) only.
MDVN' s ROA (%) Range Over the Past 10 Years
Min: -68.11  Med: -16.91 Max: 42.39
Current: -13.9
-68.11
42.39
ROC (Joel Greenblatt) (%) -133.44
MDVN's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -366.92 vs. MDVN: -133.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDVN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -201825  Med: -4226.22 Max: 299.97
Current: -133.44
-201825
299.97
Revenue Growth (3Y)(%) 65.20
MDVN's Revenue Growth (3Y)(%) is ranked higher than
92% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. MDVN: 65.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDVN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100 Max: 113.1
Current: 65.2
0
113.1
» MDVN's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

MDVN Guru Trades in Q3 2015

Paul Tudor Jones 12,934 sh (New)
Steven Cohen 1,641,334 sh (+1562.95%)
Ken Fisher 6,300 sh (+162.50%)
Joel Greenblatt Sold Out
Jim Simons 694,700 sh (-12.63%)
» More
Q4 2015

MDVN Guru Trades in Q4 2015

Pioneer Investments 149,693 sh (New)
Paul Tudor Jones 127,060 sh (+882.37%)
Steven Cohen 2,002,700 sh (+22.02%)
Ken Fisher 6,615 sh (+5.00%)
Jim Simons Sold Out
» More
Q1 2016

MDVN Guru Trades in Q1 2016

Joel Greenblatt 327,094 sh (New)
Andreas Halvorsen 707,319 sh (New)
Jim Simons 207,600 sh (New)
Columbia Wanger 1,780,000 sh (New)
Paul Tudor Jones 661,185 sh (+420.37%)
Pioneer Investments 400,496 sh (+167.54%)
Ken Fisher 6,631 sh (+0.24%)
Steven Cohen 291,100 sh (-85.46%)
» More
Q2 2016

MDVN Guru Trades in Q2 2016

Mario Gabelli 20,200 sh (New)
George Soros 12,800 sh (New)
Eric Mindich 3,082,209 sh (New)
Lee Ainslie 52,620 sh (New)
Samuel Isaly 292,900 sh (New)
Jim Simons 852,100 sh (+310.45%)
Steven Cohen 433,200 sh (+48.81%)
Joel Greenblatt 348,619 sh (+6.58%)
Andreas Halvorsen Sold Out
Ken Fisher 6,591 sh (-0.60%)
Pioneer Investments 253,445 sh (-36.72%)
Columbia Wanger 426,668 sh (-76.03%)
Paul Tudor Jones 3,500 sh (-99.47%)
» More
» Details

Insider Trades

Latest Guru Trades with MDVN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:GMXAY, OTCPK:NVZMY, NAS:JAZZ, NAS:INCY, OTCPK:GIKLY, NAS:BMRN, OTCPK:UCBJY, NAS:ALKS, NAS:SGEN, NAS:ALNY, NAS:UTHR, NAS:TSRO, OTCPK:ALIOY, NAS:ANAC, NAS:ICPT, NAS:IONS, NAS:TECH, NAS:ACAD, NAS:JUNO, NYSE:XON » details
Traded in other countries:WMD.Germany,
Medivation Inc is a biopharmaceutical company engaged in the development of novel small molecule drugs to treat diseases like Alzheimer's disease and Huntington disease.

Medivation Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI enzalutamide capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics Inc or MPT, Medivation Neurology Inc or MNI, Medivation Technologies Inc, or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Ratios

vs
industry
vs
history
Forward P/E 56.50
MDVN's Forward P/E is ranked lower than
85% of the 61 Companies
in the Global Biotechnology industry.

( Industry Median: 21.05 vs. MDVN: 56.50 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 24.89
MDVN's P/B is ranked lower than
92% of the 834 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. MDVN: 24.89 )
Ranked among companies with meaningful P/B only.
MDVN' s P/B Range Over the Past 10 Years
Min: 5.47  Med: 40.32 Max: 2053.33
Current: 24.89
5.47
2053.33
P/S 13.13
MDVN's P/S is ranked higher than
50% of the 681 Companies
in the Global Biotechnology industry.

( Industry Median: 11.12 vs. MDVN: 13.13 )
Ranked among companies with meaningful P/S only.
MDVN' s P/S Range Over the Past 10 Years
Min: 4.43  Med: 15.13 Max: 43.53
Current: 13.13
4.43
43.53
PFCF 44.43
MDVN's PFCF is ranked lower than
61% of the 127 Companies
in the Global Biotechnology industry.

( Industry Median: 27.82 vs. MDVN: 44.43 )
Ranked among companies with meaningful PFCF only.
MDVN' s PFCF Range Over the Past 10 Years
Min: 2.96  Med: 33.67 Max: 260.74
Current: 44.43
2.96
260.74
POCF 40.80
MDVN's POCF is ranked lower than
63% of the 187 Companies
in the Global Biotechnology industry.

( Industry Median: 22.41 vs. MDVN: 40.80 )
Ranked among companies with meaningful POCF only.
MDVN' s POCF Range Over the Past 10 Years
Min: 2.96  Med: 30.93 Max: 206.47
Current: 40.8
2.96
206.47
Current Ratio 4.32
MDVN's Current Ratio is ranked higher than
50% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.28 vs. MDVN: 4.32 )
Ranked among companies with meaningful Current Ratio only.
MDVN' s Current Ratio Range Over the Past 10 Years
Min: 1.46  Med: 3.87 Max: 27.3
Current: 4.32
1.46
27.3
Quick Ratio 4.32
MDVN's Quick Ratio is ranked higher than
52% of the 915 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. MDVN: 4.32 )
Ranked among companies with meaningful Quick Ratio only.
MDVN' s Quick Ratio Range Over the Past 10 Years
Min: 1.46  Med: 3.87 Max: 27.3
Current: 4.32
1.46
27.3
Days Sales Outstanding 80.78
MDVN's Days Sales Outstanding is ranked lower than
63% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.43 vs. MDVN: 80.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDVN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.21  Med: 98.56 Max: 151.52
Current: 80.78
34.21
151.52

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.10
MDVN's 3-Year Average Share Buyback Ratio is ranked higher than
78% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. MDVN: -3.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDVN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -199.7  Med: -6.9 Max: 2.2
Current: -3.1
-199.7
2.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 9.73
MDVN's Price/Projected FCF is ranked lower than
73% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.26 vs. MDVN: 9.73 )
Ranked among companies with meaningful Price/Projected FCF only.
MDVN' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.65  Med: 7.59 Max: 110.11
Current: 9.73
1.65
110.11
Price/Median PS Value 0.87
MDVN's Price/Median PS Value is ranked higher than
69% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. MDVN: 0.87 )
Ranked among companies with meaningful Price/Median PS Value only.
MDVN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.29  Med: 1.14 Max: 12.6
Current: 0.87
0.29
12.6
Earnings Yield (Greenblatt) (%) -1.99
MDVN's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 914 Companies
in the Global Biotechnology industry.

( Industry Median: -8.60 vs. MDVN: -1.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDVN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.4  Med: 3.3 Max: 8.3
Current: -1.99
-2.4
8.3

More Statistics

Revenue (TTM) (Mil) $1,027
EPS (TTM) $ -1.10
Beta1.33
Short Percentage of Float2.06%
52-Week Range $26.41 - 80.67
Shares Outstanding (Mil)165.93

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 917 1,208 1,429
EPS ($) 1.48 2.28 3.10
EPS w/o NRI ($) 1.48 2.28 3.10
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:MDVN

Headlines

Articles On GuruFocus.com
Pfizer Acquires Medivation Aug 22 2016 
Sam Isaly's Top Investments of the Year Aug 01 2016 
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Jul 29 2016 
Steven Cohen Trims Nike, Coach, Alphabet May 20 2016 
Stocks Fisher Investments Has Bought for Past 2 Quarters May 03 2016 
Weekly Insider Sells: Medivation, JPMorgan Chase, Stryker, Sabre Jan 26 2016 
Brean Capital Weighs in on Medivation Following Update on TERRAIN Study Mar 26 2015 
Wedbush Weighs in on Medivation Following Phase II TERRAIN Study Results Feb 03 2015 
Weekly CEO Sells Highlight: QAD Inc, Orbitz Worldwide Inc, Constellation Brands Inc, and Medivation Jan 25 2015 
William Blair’s Top BioPharmaceutical Stock Picks for Q1 2015 Dec 23 2014 

More From Other Websites
SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of The Board of Directors of... Aug 23 2016
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of... Aug 23 2016
Pfizer & Medivation: A Big Win Like Gilead-Pharmasset or a Big Bust Like Bristol-Inhibitex? Aug 23 2016
Stock Market News for August 23, 2016 Aug 23 2016
4 Biotech Buyout Targets for Gilead, Sanofi After Medivation Miss Aug 23 2016
Deals of the Day: Apple Gets a Gliimpse, Pfizer's Steep Price Aug 23 2016
Pfizer’s Medivation Acquisition: What You Need to Know Aug 23 2016
Pfizer Has Had A Busy M&A Year...Or Has It? Aug 23 2016
Medivation (MDVN) Stock Downgraded After Pfizer Deal Aug 23 2016
Medivation downgraded by Credit Suisse, Stifel and Maxim Group Aug 23 2016
Pfizer to Buy Medivation for $14B, Boost Cancer Franchise (revised) Aug 23 2016
GLOBAL MARKETS-Stocks creep up amid Fed limbo, dollar dips Aug 23 2016
Pfizer acquires biotech firm Medivation for $14 billion Aug 23 2016
PRESS DIGEST- New York Times business news - Aug 23 Aug 22 2016
[$$] Pfizer to Buy Medivation for $14 Billion Aug 22 2016
[$$] Medivation Ovation: Pfizer Pays the Price for Growth Aug 22 2016
M&A is key to Pfizer's sales growth: Strategist Aug 22 2016
The $150 million winner — and the losers — in Pfizer's $14 billion takeout of Medivation Aug 22 2016
Pfizer to pay $14 billion for Medivation, whose drug Xtandi was discovered by UCLA Aug 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)